T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (613)	8/24/2001 7:32:02 PM
From: Doc Bones	Read Replies (1) of 2243

Biospace.com e-mail today references this ONXX Report from SCO: biospace.com Onyx Pharmaceuticals Research Report We are initiating coverage of ONXX with a BUY rating. Our aggressive rating at this time is prompted by the stock's recent weakness after the announcement of a restructuring of the Company's corporate partnership with Pfizer. The most important part of the new agreement is that, going forward, ONXX will take over full responsibility for developing ONYX-015 for the treatment of local tumors-the Company will in turn retain all revenue from sales of the product for such indications. Pfizer will be responsible for performing and funding all clinical development work of intravenous applications of ONYX-015. Importantly, should Pfizer achieve regulatory approval for an IV application the agreement reverts to its original terms in which the two companies would co-promote the product, with each sharing profits equally. We believe the market has fundamentally misinterpreted the partnership restructuring; indeed, we feel the new deal is a highly favorable development for ONXX for the following reasons: While it will require increased initial investment, we believe the new agreement will ultimately facilitate the Company's evolution into a fully integrated specialty oncology company, largely independent of big pharma. 2) We believe ONYX-015 has the greatest chance of success in the treatment of local-regional disease, the applications for which ONXX now has full rights. Adenovirus is not a blood-borne virus and its clearance from blood is very effective. Like many other viruses, adenovirus is rapidly cleared by the liver. Additionally, most patients produce neutralizing antibodies to adenovirus. These factors could clearly limit ONYX-015's ability to reach metastatic tissue when administered intravenously and represent significant obstacles to developing the agent as systemic therapy. We therefore view systemic use of ONYX-015 as a call option on the stock rather than the primary investment thesis ---- Full Report (with graphics): smallcapsonline.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next